TY - JOUR
T1 - Primary Advanced Squamous Cell Carcinoma of the Temporal Bone
T2 - A Single-Center Clinical Study
AU - Komune, Noritaka
AU - Noda, Teppei
AU - Kogo, Ryunosuke
AU - Miyazaki, Masaru
AU - Tsuchihashi, Nana A.
AU - Hongo, Takahiro
AU - Koike, Kensuke
AU - Sato, Kuniaki
AU - Uchi, Rhutaro
AU - Wakasaki, Takahiro
AU - Matsumoto, Nozomu
AU - Yasumatsu, Ryuji
AU - Nakagawa, Takashi
N1 - Publisher Copyright:
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.
PY - 2021/2
Y1 - 2021/2
N2 - Objectives/Hypothesis: The extreme rarity of temporal bone squamous cell carcinoma (TB-SCC) has delayed the accumulation of high-quality clinical evidence. For the purposes of retrospective meta-analysis in the future, a large dataset with information from various institutions would be ideal. Our objective here was to retrospectively review cases of TB-SCC encountered at a single tertiary referral center and explore survival outcomes and prognostic factors. Study Design: Retrospective chart review. Methods: The medical records of all TB-SCC cases were retrospectively reviewed. The resulting dataset contained 71 cases of primary cancer eligible for initial definitive (curative) treatment. Results: T4 status was associated with lower disease-specific 5-year survival than T1 to T3 staging (T1: 100%, T2: 92%, T3: 86%, T4: 51%). Survival was significantly higher in operable than in inoperable cases, even when restricted to advanced (T3/T4) cancers. The tumor extension to the middle ear cavity was observed in 13/17 of T3 cases, but it was not associated with poor survival. In addition, among operable cases, negative surgical margins were associated with significantly higher survival than positive margins. Conclusions: Definitive treatments can offer disease-specific 5-year survival of over 85% in T1 to T3 cases of TB-SCC. The tumor extension to the middle ear cavity is not associated with poor survival. T4 status, inoperability, nodal invasion, and positive surgical margin are identified as a predictor of poor prognosis. Still, the matter of how to deal with unresectable tumors remains an outstanding issue in the treatment of TB-SCC. Level of Evidence: 4 Laryngoscope, 131:E583–E589, 2021.
AB - Objectives/Hypothesis: The extreme rarity of temporal bone squamous cell carcinoma (TB-SCC) has delayed the accumulation of high-quality clinical evidence. For the purposes of retrospective meta-analysis in the future, a large dataset with information from various institutions would be ideal. Our objective here was to retrospectively review cases of TB-SCC encountered at a single tertiary referral center and explore survival outcomes and prognostic factors. Study Design: Retrospective chart review. Methods: The medical records of all TB-SCC cases were retrospectively reviewed. The resulting dataset contained 71 cases of primary cancer eligible for initial definitive (curative) treatment. Results: T4 status was associated with lower disease-specific 5-year survival than T1 to T3 staging (T1: 100%, T2: 92%, T3: 86%, T4: 51%). Survival was significantly higher in operable than in inoperable cases, even when restricted to advanced (T3/T4) cancers. The tumor extension to the middle ear cavity was observed in 13/17 of T3 cases, but it was not associated with poor survival. In addition, among operable cases, negative surgical margins were associated with significantly higher survival than positive margins. Conclusions: Definitive treatments can offer disease-specific 5-year survival of over 85% in T1 to T3 cases of TB-SCC. The tumor extension to the middle ear cavity is not associated with poor survival. T4 status, inoperability, nodal invasion, and positive surgical margin are identified as a predictor of poor prognosis. Still, the matter of how to deal with unresectable tumors remains an outstanding issue in the treatment of TB-SCC. Level of Evidence: 4 Laryngoscope, 131:E583–E589, 2021.
UR - http://www.scopus.com/inward/record.url?scp=85083169760&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083169760&partnerID=8YFLogxK
U2 - 10.1002/lary.28653
DO - 10.1002/lary.28653
M3 - Article
C2 - 32267551
AN - SCOPUS:85083169760
SN - 0023-852X
VL - 131
SP - E583-E589
JO - Laryngoscope
JF - Laryngoscope
IS - 2
ER -
